Pharma BD Deal Intelligence
Vertex Pharmaceuticals Inc. / Exonics Therapeutics
2005 · Acquisition/Merger · $1.0B · Complete
Announcement Sentiment
88
Strongly positive
Outcome Score
54
Mixed — partial payoff, real shortfalls.
Vertex acquired Exonics for up to $1B for Duchenne muscular dystrophy treatments.
Key facts
- Announced May 20, 2005
- Closed Jul 31, 2019
- Deal value $1.0B
- Deal type Acquisition/Merger
- Therapeutic area Rare Disease
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals